Pfizer introduces latest cost-saving initiative

Pfizer Launches Multiyear Program to Reduce Costs and Rebound from Covid Business Decline

Pfizer, the pharmaceutical giant, announced on Wednesday the launch of a new multiyear program aimed at reducing costs and recovering from the rapid decline of its Covid business. This initiative comes on the heels of a previous $4 billion cost-cutting effort that Pfizer had announced last year, in response to decreased demand for its Covid vaccine and oral drug Paxlovid.

In a securities filing, Pfizer revealed that the first phase of this new program will focus on operational efficiencies and is expected to save the company approximately $1.5 billion by the end of 2027. However, there will be one-time costs associated with the initial phase, totaling around $1.7 billion, including severance for an undisclosed number of laid-off employees. These charges are expected to be recorded predominantly this year.

The program is also set to involve “product portfolio enhancements” and modifications to Pfizer’s manufacturing and supply network, according to a spokesperson. The company aims to streamline its ways of working, reduce complexity, and increase productivity in Pfizer Global Supply through this program.

Given the complexity of manufacturing and the longer lead times required to implement changes, Pfizer anticipates that this program will be executed in multiple phases. The ultimate goal is to shore up investor sentiment and regain market value, as Pfizer’s shares plummeted nearly 50% in 2023, making it the worst-performing pharmaceutical stock that year.

Despite disappointing Wall Street with the underwhelming launch of a new RSV shot and a weight loss pill that failed to meet expectations, Pfizer managed to please investors with its first-quarter financial results that exceeded expectations. The company reported higher revenue and adjusted profit, prompting an increase in its full-year earnings outlook.

Pfizer’s CEO, Albert Bourla, expressed cautious optimism about the company’s prospects for the year ahead. Following the positive earnings report, Pfizer’s stock rose by 6%, and it has since climbed by almost 14%.

Overall, Pfizer’s new cost-cutting program signals the company’s commitment to adapting to changing market conditions and enhancing its operational efficiency, as it strives to bounce back from the challenges of the past year.

Back To Top